CHARLOTTE, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced an update to its previously announced voluntary warrant exchange program. Updated Participation and Impact In connection with the Company’s prior financing round in October 2025, 2,722,642 Class A ordinary shares were issued, with one Class A warrant and one Class B warrant issued ...

Core Viewpoint - Prenetics Global Limited has initiated a warrant exchange program to simplify its capital structure and reduce potential future dilution, with approximately 83.4% of outstanding Class A and Class B warrants participating in the exchange [1][2][3] Warrant Exchange Program - The program was developed based on feedback from institutional shareholders who supported consolidating legacy warrants into a cleaner structure [2] - The exchange agreements cover 4,539,722 of the 5,445,284 total Class A and Class B warrants, representing approximately 83.4% participation [3] Summary of the Warrant Exchange - The Company can exercise its forced-redemption right only after the registration statement for Class C warrants is effective and if Class A shares trade at or above $21.60 for ten consecutive trading days [4] - All eligible warrant holders were offered identical terms for participation in the exchange [5] Impact on Capital Structure - Approximately 4.54 million Class A and Class B warrants are expected to be exchanged for about 2.27 million Class C warrants [6] - Post-exchange, the total number of outstanding warrants is expected to be around 3.18 million, a reduction of approximately 42.0% from the original issuance in October 2025, with potential for up to 50% reduction if all holders participate [7] Strategic Rationale and Benefits - The exchange offers several benefits, including the consolidation of two legacy warrant classes into one Class C warrant with a lower exercise price of $18.00 and a two-year term [9] - Participation from the largest institutional investors indicates strong confidence in the revised structure and its long-term benefits [10] Company Overview - Prenetics is a leading health sciences company focused on health and longevity, with its IM8 brand achieving over $100 million in annual recurring revenue within 11 months of launch [11] - IM8 combines advanced science with natural ingredients to provide a holistic approach to health, featuring products like Daily Ultimate Essentials [12]

Core Points - Abacus Global Management, Inc. announced the expiration and results of its exchange offer and consent solicitation for outstanding public and private placement warrants [1][2] - Approximately 88% of the outstanding warrants were validly tendered, and the company expects to accept all validly tendered warrants for exchange [2] - The company received approval from parties representing approximately 83% of the outstanding public warrants and 94% of the outstanding private placement warrants for a warrant agreement amendment [2] - The exchange ratio for the post-offer exchange will be 0.207 shares of common stock per warrant, which is 10% less than the initial exchange ratio [2] Company Overview - Abacus Global Management specializes in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services [6] - The company focuses on longevity-based assets and personalized financial planning, leveraging proprietary data analytics and industry expertise [6] Regulatory Information - A registration statement on Form S-4 for the common stock issuable in the offer was declared effective by the SEC on July 28, 2025 [5]